1.42
+0.03(+2.16%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 15, 2021
| Name | Title | Pay | Year Born |
| Pierluigi Paracchi | Co-Founder, Chairman, CEO & GM | 0 | 1973 |
| Bernard Rudolph Gentner | CO-Founder & Scientific Advisory Board Member | 0 | 1975 |
| Francesco Galimi | Acting Chief Medical Officer, Head of Development & Director | 0 | 1968 |
| Luigi Naldini | Co-Founder & Chairman of Scientific Advisory Board | 0 | 1959 |
| Stefania Mazzoleni | Director of Program Development | 0 | 1982 |
| Richard Slansky | Chief Financial Officer | 0 | 1958 |
| Barbara Regonini | Director of Finance | 0 | 1973 |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.